Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
Methods in Molecular Medicine
|
March 11, 2011
A Phase II Trial of Intratumoral Injection with a Selectively Replicating Adenovirus (ONYX-015) in Patients with Recurrent, Refractory Squamous Cell Carcinoma of the Head and Neck
D H Kirn
The Journal of Clinical Investigation
|
April 5, 2000
Replication-selective microbiological agents: fighting cancer with targeted germ warfare
D H Kirn
Gene Therapy
|
June 14, 2000
A tale of two trials: selectively replicating herpesviruses for brain tumors
D H Kirn
The Journal of Clinical Investigation
|
April 5, 2000
Replication-selective adenoviruses as oncolytic agents
C Heise, D H Kirn
Journal of the National Cancer Institute
|
June 5, 1996
Long-term freedom from disease progression with interferon alfa therapy in two patients with malignant hemangiopericytoma
D H Kirn, A Kramer
Molecular Medicine Today
|
December 1, 1996
Replicating viruses as selective cancer therapeutics
D H Kirn, F McCormick
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
March 18, 2005
Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development
Terry W Hermiston, D H Kirn
Cancer Gene Therapy
|
December 23, 1999
Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects
C C Heise, A Williams, J Olesch, et al.
Gene Therapy
|
August 27, 2010
Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1
B Huang, R Sikorski, D H Kirn, et al.
Bulletin of Mathematical Biology
|
August 11, 2001
Modeling and analysis of a virus that replicates selectively in tumor cells
J T Wu, H M Byrne, D H Kirn, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
Methods in Molecular Medicine
|
March 11, 2011
A Phase II Trial of Intratumoral Injection with a Selectively Replicating Adenovirus (ONYX-015) in Patients with Recurrent, Refractory Squamous Cell Carcinoma of the Head and Neck
D H Kirn
The Journal of Clinical Investigation
|
April 5, 2000
Replication-selective microbiological agents: fighting cancer with targeted germ warfare
D H Kirn
Gene Therapy
|
June 14, 2000
A tale of two trials: selectively replicating herpesviruses for brain tumors
D H Kirn
The Journal of Clinical Investigation
|
April 5, 2000
Replication-selective adenoviruses as oncolytic agents
C Heise, D H Kirn
Journal of the National Cancer Institute
|
June 5, 1996
Long-term freedom from disease progression with interferon alfa therapy in two patients with malignant hemangiopericytoma
D H Kirn, A Kramer
Molecular Medicine Today
|
December 1, 1996
Replicating viruses as selective cancer therapeutics
D H Kirn, F McCormick
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
March 18, 2005
Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development
Terry W Hermiston, D H Kirn
Cancer Gene Therapy
|
December 23, 1999
Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects
C C Heise, A Williams, J Olesch, et al.
Gene Therapy
|
August 27, 2010
Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1
B Huang, R Sikorski, D H Kirn, et al.
Bulletin of Mathematical Biology
|
August 11, 2001
Modeling and analysis of a virus that replicates selectively in tumor cells
J T Wu, H M Byrne, D H Kirn, et al.
Page
of 3